US · Healthcare · Diagnostics & Research
EPS came in at -0.33 against a street estimate of -0.08 — a miss of 312.5%.
Analysts rate Myriad Genetics Inc a hold (1 buy, 5 hold, 3 sell out of 9) with an average price target of $4.11.
| Fund | Stake |
|---|---|
| BlackRock Inc | 11.39% |
| Millennium Management LLC | 6.93% |
| Vestal Point Capital LP | 6.00% |
| State Street Corp | 5.21% |
| D. E. Shaw & Co LP | 4.79% |
| Vanguard Capital Management, LLC | 4.27% |
| Acadian Asset Management LLC | 3.27% |
| Vanguard Portfolio Management, LLC | 3.22% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Myriad Genetics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.